DAIC

JANUARY 23, 2024

In the hospital setting, CMS increased payment for the FFRCT service by ~7% for 2024. Better reimbursement for hospitals leads to improved accessibility to this technology, which is a win for everyone involved, most notably patients.” The new code can be used for hospital outpatient, physician offices, or imaging centers.

Reimbursement 105

Reimbursement Coronary Artery Disease CMS Technology 105

CardiacWire

DECEMBER 10, 2023

An international research team used Us2.ai’s with HFpEF) That last part is notable from an echo AI adoption perspective, given that CMS recently approved an outpatient reimbursement code for AI-based HFpEF detection ($285 per use) It could also prove to be notable for Us2.ai, The post Us2.ai’s

Heart Failure 59

Heart Failure Reimbursement CMS Outpatient 59

DAIC

MARCH 13, 2024

CMS has reviewed the CardiAMP Heart Failure II Trial and approved the investigational product, related and routine items and services for purposes of Medicare coverage. CMS has reviewed the CardiAMP Heart Failure II Trial and approved the investigational product, related and routine items and services for purposes of Medicare coverage.

CMS 111

CMS Heart Failure Reimbursement Quality of Life 111

CardiacWire

JANUARY 8, 2025

The buzz around artificial intelligences impact on cardiology keeps growing louder, and thats proving to be particularly true in the AI-ECG segment, with 2025 already off to a strong start from ECG startups and researchers alike. AI and ECG pair well due to the strong pattern recognition that machine learning algorithms can achieve.

Cardiac Arrest 59

Cardiac Arrest Reimbursement CMS Risk Factors 59

DAIC

JULY 25, 2024

The CardiAMP clinical development for heart failure is supported by the Maryland Stem Cell Research Fund and is reimbursed by Center for Medicare and Medicaid Services (CMS) for both treatment and control procedures. CAUTION - Limited by United States law to investigational use.

Heart Failure 111

Heart Failure Quality of Life CMS Reimbursement 111

DAIC

MARCH 7, 2024

The data was presented today by Amish Raval , MD, Director of Clinical Cardiovascular Research and Professor of Medicine at the University of Wisconsin-Madison at the Technology and Heart Failure Therapeutics (THT) 2024 annual meeting. The CardiAMP HF II trial is expected to similarly secure CMS reimbursement.

Heart Failure 105

Heart Failure Biomarkers Reimbursement CMS 105